1 Abstract
Triple-Negative Breast Cancer (TNBC) is a rare cancer, characterized by high metastatic potential and poor prognosis, and has limited treatment options compared to other breast cancers. The current standard of care in non-metastatic settings is neoadjuvant chemotherapy (NACT), with the goal of breast-conserving surgery and for an in vivo assessment of chemosensitivity. However, the efficacy of this treatment varies significantly across patients, and this histological response heterogeneity is still poorly understood partly due to the paucity of available curated TNBC data. Motivated by this problem, we investigate the use of machine learning (ML) to predict at diagnosis the histological response to NACT for early TNBC patients. To overcome the known biases of related small scale studies while respecting data privacy, we conduct, for the first time, a TNBC study in a multi-centric fashion behind hospitals’ firewalls using collaborative Federated Learning (FL). Thereby allowing access to enough TNBC data to sustain a complete response heterogeneity investigation. We show evidence that local ML models relying on Whole-Slide Images (WSIs) at diagnosis are able to predict the histological response to NACT as accurately as current clinical approaches, which rely on time-consuming expert annotations. We demonstrate that collaborative training further improves performance over single-center training outperforming clinical methods. Our ML model is interpretable by design, and we show that it is sensitive to specific histological patterns. While we identify known predictive biomarkers among them, this proof of concept for real-world collaborative FL paves the way for future biomarker discovery using unprecedently large datasets.
Competing Interest Statement
Fundings: As described in the acknowledgments this work received the financial support of the French BPI through the HealthChain project (https://www.substra.ai/en/healthchain-project). Some authors are employed by Owkin, Inc.. (J.O.d.T., C.B., M.A., Ch.M., B.S., E.B., M.Z., G.W., K.M., C.G., I.D., A.-L.M., Ca.M., M.G.) Personal fundings: G.W. is Co-founder of Owkin. P.-E.H. reports grants, personal fees and non-financial support from PFIZER, grants and non-financial support from NOVARTIS, grants and non-financial support from ROCHE, grants, personal fees and non-financial support from Astrazeneca, personal fees and non-financial support from Mylan, grants, personal fees and non-financial support from Pierre Fabre, personal fees and non-financial support from AMGEN and personal fees and non-financial support from SEAGEN outside the submitted work. E.W.T. did this work while employed at Owkin, Inc. and is now employed by Amazon.
Funding Statement
Fundings: As described in the acknowledgments this work received the financial support of the French BPI through the HealthChain project (https://www.substra.ai/en/healthchain-project). Some authors are employed by Owkin, Inc.. (J.O.d.T., C.B., M.A., Ch.M., B.S., E.B., M.Z., G.W., K.M., C.G., I.D., A.-L.M., Ca.M., M.G.) Personal fundings: G.W. is Co-founder of Owkin. P.-E.H. reports grants, personal fees and non-financial support from PFIZER, grants and non-financial support from NOVARTIS, grants and non-financial support from ROCHE, grants, personal fees and non-financial support from Astrazeneca, personal fees and non-financial support from Mylan, grants, personal fees and non-financial support from Pierre Fabre, personal fees and non-financial support from AMGEN and personal fees and non-financial support from SEAGEN outside the submitted work. E.W.T. did this work while employed at Owkin, Inc. and is now employed by Amazon.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IRB of Institut Curie (Comité de Revue Institutionnelle - CRI Data) and the IRB of Centre Léon Bérard (Artificial Intelligence Project Evaluation Board) both validated the ethics of the current study inside the HealthChain project.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵† co-last
Data Availability
Data is available upon reasonable and GDPR compliant request from Institut Curie and Centre Léon Bérard
